title: [Pharmacological recommendations in the daily metabolic control of diabetes mellitus type 2. The role of the new insulins].
abstract: The epidemic of type 2 diabetes in the latter part of the 20th and early 21st centuries and the recognition that achieving specific glycemic goals can substantially reduce morbidity, have made effective treatment of hyperglycemia a top priority. In addition, strict control of the multiple, classical and emergent cardiovascular risk factors are also important. Diabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. The development of new classes of blood glucose-lowering medications such as glitazones to supplement the classical therapies such as sulfonylureas and metformin has increased oral treatment options for type 2 diabetes. Combined therapy of two oral agents is the essential axis of type 2 diabetic patients. Early insulin therapy in combined therapy is presently an option according to ADA-2007 Standards.
authors: Unidad de Riesgo Cardiometabólico y Patología Endotelial, Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España.
authors: O
authors: O
authors: Sánchez Sánchez
authors: J
authors: J
authors: Sabán Ruiz
mesh_terms: D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D010353:Patient Education as Topic; D012307:Risk Factors; D012648:Self Care; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D008687:Metformin